| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals Inc. | REC-4881 | AXIN1 or APC Mutant Cancers | Phase 2 | Withdrawn | Oral | Oncology |
| Recursion Pharmaceuticals Inc. | REC-3964 - (ALDER) | Clostridium Difficile Infection | Phase 2 | Trial Planned | Intravenous | Gastroenterology |
| Recursion Pharmaceuticals Inc. | REC-4881 - (TUPELO) | Familial adenomatous polyposis (FAP) | Phase 2 | Data Released | oral | Genetic Disorder |
| Recursion Pharmaceuticals Inc. | REC-994 - (SYCAMORE) | Cerebral Cavernous Malformation (CCM) | Phase 2a | Trial Discontinued | Oral | Neurology |
| Redhill Biopharma Ltd. | RHB-204 | Nontuberculous mycobacteria (NTM) infections | Phase 3 | Ongoing | Oral | Antibiotic |
| Redhill Biopharma Ltd. | RHB-104 MAP | Crohn’s disease | Phase 3 | Trial Completed | Oral | Gastroenterology |
| Redhill Biopharma Ltd. | BEKINDA | Gastroenteritis | Phase 3 | Trial Completed | Oral | Gastroenterology |
| Redhill Biopharma Ltd. | RHB-107 (upamostat) | COVID-19 (outpatients) | Phase 2/3 | Looking for Funding | oral | COVID-19 |